Your session is about to expire
← Back to Search
TAA-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM Trial)
TACTAM Trial Summary
This trial is for patients with Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS), or smoldering myeloma (SM). The goal is to find the largest safe dose of TAA-specific CTLs (a new experimental therapy), and to see whether it might help patients by targeting proteins that are expressed by cancer cells.
TACTAM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTACTAM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TACTAM Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 or older with high risk MGUS or smoldering myeloma.I am 18 or older with high risk MGUS/smoldering myeloma or have multiple myeloma and received treatment.I am 18 or older with a high-risk MGUS or smoldering myeloma diagnosis.I am not pregnant and willing to use effective birth control or my partner will use a condom.My kidney function, measured by creatinine, is within twice the normal limit for my age.I haven't taken any standard cancer treatments except for certain medications in the last 48 hours.My oxygen level is above 93% without extra oxygen, after having radiation therapy.You have an ongoing HIV infection at the time of blood collection.I am currently suffering from a severe infection.I am currently suffering from a severe infection.I am over 18, have Myeloma, and have been treated before. If I had a stem cell transplant, it was over 90 days ago.My bilirubin and AST levels are within acceptable limits, and my hemoglobin is at least 7.0.My white blood cell count is healthy following a transplant.I have taken corticosteroids within 2 days before receiving a CTL infusion.I am able to live with some level of independence.I had a stem cell transplant less than 90 days ago.Your hemoglobin level is 7.0 or higher.
- Group 1: Group A
- Group 2: Group B
- Group 3: Group C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many volunteers have signed up for this clinical investigation?
"Affirmative. The clinicaltrials.gov website displays that this medical study, which was first posted on April 1st 2015 is still searching for participants to take part in it. 36 individuals are required from one location."
Does a fixed dose of TAA-specific CTLs pose any potential risks to human health?
"Our team has assigned TAA-specific CTLs- fixed dose a safety rating of 1, as this is an early phase clinical trial and there are only scant data proving it both safe and effective."
Is this research endeavor still accepting participants?
"According to clinicaltrials.gov, this trial is actively seeking participants and was initially launched on April 1st 2015 with the most recent update occurring on November 11th 2022."
Share this study with friends
Copy Link
Messenger